Top Markets
#1 TENDIES TENDIES +60.15%
#2 Threshold Network Threshold Network +48.72%
#3 Akedo Akedo +24.88%
#4 Cash Cat Cash Cat +21.86%
#5 Kinetiq Kinetiq +16.38%
#6 OSK OSK +16.37%
#7 Maple Finance Maple Finance +13.27%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Magma Finance Magma Finance +12.46%
#10 Falcon Finance Falcon Finance +11.62%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Rank in Stocks #17187
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Share Price
$3.55
Market Cap
$256.68M
Change (1 day)
4.98%
Change (1 year)
37.99%
Country
FR
Trade Cellectis S.A. (ALCLS)

Category

Healthcare
Dividend history for Cellectis S.A. (ALCLS)
Cellectis S.A. (stock symbol: ALCLS) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Cellectis S.A. (ALCLS) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH